Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2023 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
March 01, 2023 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care...
February 23, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced...
February 16, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
February 02, 2023 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on...
January 03, 2023 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
November 07, 2022 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision...
November 03, 2022 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society...
October 27, 2022 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
September 26, 2022 07:30 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...